Novel approaches targeting mitochondrial fission to deplete stem-like tumor cells in prostate cancer and improve treatment outcomes

Antonino Passaniti^{1

2

3

4}, Arif Hussain^{1

2

3

4}

Affiliations

¹ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
² Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA.
³ The Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
⁴ The Veteran's Health Administration Research & Development Service, Baltimore, MD, USA.

Editorial

Antonino Passaniti et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S335.

doi: 10.21037/atm.2019.09.109.

Antonino Passaniti^{1

2

3

4}, Arif Hussain^{1

2

3

4}

¹ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
² Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA.
³ The Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
⁴ The Veteran's Health Administration Research & Development Service, Baltimore, MD, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.
Civenni G, Bosotti R, Timpanaro A, Vàzquez R, Merulla J, Pandit S, Rossi S, Albino D, Allegrini S, Mitra A, Mapelli SN, Vierling L, Giurdanella M, Marchetti M, Paganoni A, Rinaldi A, Losa M, Mira-Catò E, D'Antuono R, Morone D, Rezai K, D'Ambrosio G, Ouafik L, Mackenzie S, Riveiro ME, Cvitkovic E, Carbone GM, Catapano CV. Civenni G, et al. Cell Metab. 2019 Aug 6;30(2):303-318.e6. doi: 10.1016/j.cmet.2019.05.004. Epub 2019 May 23. Cell Metab. 2019. PMID: 31130467

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
1. Merseburger AS, Haas GP, von Klot CA. An update on enzalutamide in the treatment of prostate cancer. Ther Adv Urol 2015;7:9-21. 10.1177/1756287214555336 - DOI - PMC - PubMed
1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. 10.1056/NEJMoa1014618 - DOI - PMC - PubMed
1. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152-60. 10.1016/S1470-2045(14)71205-7 - DOI - PubMed
1. Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol 2017;35:3189-97. 10.1200/JCO.2016.72.1068 - DOI - PubMed